Amantadine‐induced hypersexuality in a non‐Parkinsonian patient with catatonia: a case report.
Saved in:
| Title: | Amantadine‐induced hypersexuality in a non‐Parkinsonian patient with catatonia: a case report. |
|---|---|
| Authors: | Gasnier, Matthieu (AUTHOR), Frajerman, Ariel (AUTHOR), Haddadi, Nourredine (AUTHOR), Herrero, Hugo (AUTHOR), Faulet, Théo (AUTHOR), Martin, Severine (AUTHOR), Korngold, Julia (AUTHOR), Colle, Romain (AUTHOR), Corruble, Emmanuelle (AUTHOR), Choucha, Walid (AUTHOR) |
| Source: | Psychiatry & Clinical Neurosciences. Oct2023, Vol. 77 Issue 10, p573-574. 2p. |
| Subjects: | Hypersexuality, Catatonia |
| Abstract: | Amantadine, a non-competitive anti-NMDA receptor antagonist and a pro-dopaminergic drug, has Food and Drug Administration (FDA) and the European Medicine Agency (EMA) approval for the treatment of influenza virus and Parkinson disease. Amantadine-induced hypersexuality in a non-Parkinsonian patient with catatonia: a case report Hypersexual behaviors disappeared within 24 h, and the patient reported no recurrence of hypersexuality within the 4 weeks following amantadine discontinuation. [Extracted from the article] |
| Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
